BCR/ABL p210, Quant by RT PCR

This assay is a nucleic acid amplification test for the quantitation of BCR::ABL1 p210 transcripts (e13a2 and e14a2) in total RNA from whole blood or bone marrow aspirate. This quantitative test is recommended for therapeutic monitoring and detection of minimal residual disease for patients with an established diagnosis. The test does not differentiate between e13a2/b2a2 or e14a2/b3a2 fusion transcripts and does not detect other rare fusion transcripts resulting from t(9;22).

To facilitate the interlaboratory comparison of findings and the assessment of molecular milestones (major molecular response or MMR), results are reported using the International Scale.

For the p190 fusion form (minor breakpoint), order BCR/ABL p190, Quant by RT PCR [QP190]

For patients with uncertain diagnosis or unknown forms of BCR::ABL1 fusion transcripts, please consider ordering BCR/ABL p210, Quant Reflexive [QP210R]
The reportable range is 0.0030% to 50% IS

The limit of detection is 0.0030% IS.

Stability is 72 hrs. Specimens received after 72 hrs. will be rejected.

Limitations: This assay in unable to detect BCR::ABL1 p190, p230, or other rare transcripts.

Please complete the appropriate request form based on your patient location. Hematopathology test request form can be found at Clinical Pathology Test Order Forms.

Blood: 6mL in LAVENDER top (EDTA) (minimum total of 5 million WBC)

Bone Marrow: 1-2 mL in a LAVENDER top (EDTA) (minimum total of 5 million WBC)

Unacceptable:
Serum, plasma, extracted DNA, CSF, FFPE tissue, frozen whole blood or bone marrow.
Severely hemolyzed or clotted specimens.
Specimens with low volume or inadequate WBC.
Specimens received beyond 72hr stability limit.
Specimens collected in anticoagulants other than EDTA.